264 related articles for article (PubMed ID: 17724064)
1. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
Brown HS; Chadwick A; Houston JB
Drug Metab Dispos; 2007 Nov; 35(11):2119-26. PubMed ID: 17724064
[TBL] [Abstract][Full Text] [Related]
2. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
Brown HS; Wilby AJ; Alder J; Houston JB
Drug Metab Dispos; 2010 Dec; 38(12):2139-46. PubMed ID: 20847136
[TBL] [Abstract][Full Text] [Related]
3. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes.
Di Marco A; Yao D; Laufer R
Eur J Biochem; 2003 Sep; 270(18):3768-77. PubMed ID: 12950260
[TBL] [Abstract][Full Text] [Related]
4. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction.
Hallifax D; Houston JB
Drug Metab Dispos; 2007 Aug; 35(8):1325-32. PubMed ID: 17470525
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
Gibbs MA; Thummel KE; Shen DD; Kunze KL
Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6.
Song M; Hong M; Lee MY; Jee JG; Lee YM; Bae JS; Jeong TC; Lee S
Food Chem Toxicol; 2013 Sep; 59():549-53. PubMed ID: 23835282
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships.
Ervine CM; Matthew DE; Brennan B; Houston JB
Drug Metab Dispos; 1996 Feb; 24(2):211-5. PubMed ID: 8742233
[TBL] [Abstract][Full Text] [Related]
9. Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes.
Grime K; Webborn PJ; Riley RJ
Drug Metab Dispos; 2008 Aug; 36(8):1670-8. PubMed ID: 18474678
[TBL] [Abstract][Full Text] [Related]
10. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
[TBL] [Abstract][Full Text] [Related]
11. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
Witherow LE; Houston JB
J Pharmacol Exp Ther; 1999 Jul; 290(1):58-65. PubMed ID: 10381760
[TBL] [Abstract][Full Text] [Related]
12. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
Drug Metab Dispos; 2012 Apr; 40(4):706-16. PubMed ID: 22228749
[TBL] [Abstract][Full Text] [Related]
13. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
15. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
Ashforth EI; Carlile DJ; Chenery R; Houston JB
J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
[TBL] [Abstract][Full Text] [Related]
16. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
17. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Lu C; Hatsis P; Berg C; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
[TBL] [Abstract][Full Text] [Related]
18. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.
Gibbs MA; Kunze KL; Howald WN; Thummel KE
Drug Metab Dispos; 1999 May; 27(5):596-9. PubMed ID: 10220488
[TBL] [Abstract][Full Text] [Related]
19. A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.
Bhoopathy S; Xin B; Unger SE; Karnes HT
J Pharm Biomed Anal; 2005 Apr; 37(4):739-49. PubMed ID: 15797796
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.
Pichard L; Fabre I; Fabre G; Domergue J; Saint Aubert B; Mourad G; Maurel P
Drug Metab Dispos; 1990; 18(5):595-606. PubMed ID: 1981707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]